Organization type


  • Private research organization

Early phases


  • Biomarker identification
  • Omics
    • Epigenomics
    • Genomics
    • Metabolomics
    • Transcriptomics
  • Target identification – new biological hypothesis
  • Target validation – Hypothesis verification

Screening


  • Assay development
    • In vitro screening models
    • In vivo screening models
  • Chemical libraries
    • Small molecules (including natural product, DNA encoded libraries and fragment libraries)
  • Fragment based screening
    • Hit expansion. Medicinal chemistry programs.
    • Virtual screening
  • Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)

Optimization phases


  • In vitro biochemical models(including assay/model development and testing)
  • In vivo animal models (including assay/model development and testing)
  • Medicinal chemistry programs for hit to lead and lead optimization

Functional areas


  • Bioinformatics
  • Compound management
  • Structural biology

Terapeutic areas


  • Blood and lymphatic system
  • Cancer
  • Cardiovascular
  • Nervous Central System

Additional activities


  • Consulting services
  • Industry associations
  • Investment / fund raising activities for drug discovery